Esperion recalls Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg, 30 tablets, Rx only, Manufactured for: Esperion Therapeutics, Inc,
Recalled September 13, 2023 · FDA recall D-1143-2023 · Esperion
Hazard
Failed dissolution specifications: below specification results at stability 12-month · FDA Class III
Units
45,240 bottles
Sold at
Nationwide USA
Description
Failed dissolution specifications: below specification results at stability 12-month
Product
Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg, 30 tablets, Rx only, Manufactured for: Esperion Therapeutics, Inc, Ann Arbor, MI 48108, NDC 72426-818-03
Manufacturer(s)
Esperion
Source: U.S. Food and Drug Administration. Official recall notice on fda.gov →